Oppilotech

What Oppilotech does

Oppilotech is a privately held UK biotechnology company founded in 2014 that operates a proprietary High-Resolution Dynamic Modelling platform — branded COMET (Computationally Optimised Mechanistically Evaluated Targets) — built on systems biology and machine learning to produce detailed computational simulations of cellular processes. Its most mature model is a whole-cell dynamic model of E. coli covering more than 3,000 genes, supported by over 10 years of wet-lab in-house genomic modelling data combined with text-mined public data. The company uses the platform to identify viable drug targets and to develop first-in-class drug programmes, with active pipeline assets in Gram-negative antibacterials (OPT-200 targeting the LPS pathway at ~20% progress; OPT-500 and OPT-600 targeting isoprenoid biosynthesis) and in oncology (MAPK pathway and synthetic lethality programmes, each at ~18% progress).

The business runs three revenue streams: (i) modelling services applying the company's genomic and mechanistic models to client-specified targets, pathways, or compounds to elucidate mode of action and metabolic bypass; (ii) specialist microbiology services (MIC/MBC testing, checkerboard synergy/antagonism, time-kill analysis, resistance development profiling, MTT assays) backed by a >20,000 bacterial isolate collection; and (iii) co-development drug discovery partnerships, exemplified by the March 2022 agreement with Evariste Technologies combining Oppilotech's target identification with partner ligand discovery capabilities. GTM is consultative and science-led direct enterprise sales targeting global pharmaceutical and biotech companies as well as academic research institutions, primarily funneled through CEO-led engagement at industry events (BioEquity Europe, Bioinfect, AMR Innovation Mission).

Oppilotech Limited is registered in London at the London Bioscience Innovation Centre and operates its laboratory from Stevenage Bioscience Catalyst in Stevenage, UK. The team is small (11–50 employees) but unusually experienced for its size, including co-founders Ajay Mistry (CEO), Dr. John George (CSO), Keith Powell (Chairperson), and Cora Griffin, plus operational leadership in microbiology, finance, and business development. Capitalisation to date consists primarily of non-dilutive grant funding from CARB-X, Innovate UK, the Wellcome Trust, and the UK Department of Health and Social Care, supplemented by small angel/accelerator rounds in 2016–2018.

Name

Oppilotech

Legal name

Oppilotech Limited

Website

https://oppilotech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Oppilotech is a UK biotechnology company using its proprietary COMET high-resolution dynamic modelling platform — built on systems biology and machine learning — to identify novel drug targets and develop first-in-class antibacterials and oncology therapeutics, while offering modelling and microbiology services to pharma, biotech, and academic clients.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAGAJAO

AI/ML Platforms for Drug Discovery & Experiment Optimization

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAIALAA

Drug Discovery (Target ID/Validation & Hit Discovery)

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

SECONDARYHLAAAIAI

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Computational drug discovery
• Biochemical modelling services
• Antibacterial drug development
• Microbiology testing services
• Drug target identification

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Modelling Services: Cutting edge biochemical modelling capability offered as a service to elucidate complex biology around client targets, pathways or compounds of interest. Provides detailed understanding of biochemical bypass and modes of action.
2. Microbiology Testing Services: Specialist microbiology services including susceptibility profiling (MIC, MBC), checkerboard synergy/antagonism testing, time-kill analysis, resistance development potential determination, and MTT assays. Supports early-stage anti-infective drug development projects.
3. Drug Discovery Co-development Partnerships: Co-development partnerships with other companies (such as partnership with Evariste Technologies) to pursue drug targets discovered using Oppilotech's models, combining their computational expertise with partner ligand discovery capabilities.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Oppilotech builds and sells computational drug discovery services underpinned by its proprietary COMET High-Resolution Dynamic Modelling platform, which uses systems biology and machine learning to map cellular biochemistry and identify viable drug targets. The company packages this capability as a Modelling Service and as a specialist Microbiology Service for antimicrobial drug development, while also advancing an internal pipeline of first-in-class antibacterial and oncology programmes discovered through its models.

Product overview

Oppilotech offers a suite of computational and laboratory services for drug discovery. At its core is the COMET (Computationally Optimised Mechanistically Evaluated Targets) High-Resolution Dynamic Modelling Platform, which uses systems biology and Machine Learning to build detailed computational models of cellular processes and identify viable drug targets. This platform is complemented by biochemical Modelling Services that apply the company's modelling capabilities to client-specified targets, pathways, or compounds. Additionally, the company provides specialist Microbiology Services for antimicrobial drug development, including susceptibility testing, synergy testing, and resistance profiling. The company also maintains its own drug pipeline programmes in oncology and antibacterials based on its computational models.

Differentiator

Problem solved

Functional benefit

Brands

• COMET (Computationally Optimised Mechanistically Evaluated Targets): High-resolution modelling platform for mapping biology at unprecedented levels of detail around chosen pathways/targets

Products and services

• Modelling Services

Quantifiable outcome

• Most advanced whole cell dynamic computational model of E. coli currently available, covering over 3000 genes
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered core, strategic and minor.

• Evariste TechnologiescoreStrategic or Co-development Partner · 16 March 2022Co-development drug discovery partnership announced March 16, 2022. Oppilotech's systems biology and machine learning platform identifies viable drug targets, which Evariste Technologies pursues using its ligand discovery platform technology that can significantly cut time required to identify clinical drug candidates. The partnership aims to pursue a drug target discovered using Oppilotech's models for a first-in-class antibacterial programme.
• The Quadram InstitutestrategicStrategic or Co-development PartnerResearch institute focused on gut health, microbiology, and food science. Listed as a partner on Oppilotech's website, suggesting collaboration in bioscience research.
• KQ LabsminorStrategic or Co-development PartnerListed as a partner on Oppilotech's website.
• Cambridge UniversitystrategicStrategic or Co-development PartnerListed as a partner on Oppilotech's website.
• Accelerate BabrahamminorStrategic or Co-development PartnerListed as a partner on Oppilotech's website.
• Leeds Beckett UniversitystrategicStrategic or Co-development PartnerDr. John George joined Leeds Beckett University as a Reader in 2017. Company founded in 2014 based on his team's biochemistry work.
• University of East London (UEL)minorStrategic or Co-development PartnerListed as a partner on Oppilotech's website.
• SimcereminorStrategic or Co-development PartnerListed as a partner on Oppilotech's website.
• SBC (Stevenage Bioscience Catalyst)strategicStrategic or Co-development PartnerOppilotech's laboratory is located at Stevenage Bioscience Catalyst, suggesting an incubator/campus partnership. Listed as a partner on the website.
• Evariste TechnologiescoreTechnology or IntegrationMachine learning approach to systems biology combined with Evariste's ligand discovery platform. Evariste's compounds are tested in-house using Oppilotech's microbiology expertise and computational models.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Evotec: Large drug discovery CRO/platform offering end-to-end services from target ID through preclinical; broadly overlaps Oppilotech's services and target-discovery business at much larger scale.
• Charles River Laboratories: Large preclinical CRO with discovery, microbiology, and safety assessment services; comparable services-side offering, especially around antimicrobial microbiology testing.

Direct peers

• Exscientia: AI-driven small molecule drug discovery company that uses computational platforms to design and prioritise drug candidates; directly comparable AI-first discovery approach with pharma partnerships.
• Recursion Pharmaceuticals: AI/ML-driven drug discovery platform combining high-throughput wet-lab biology with computational models; directly comparable in using AI to generate novel therapeutic hypotheses at platform scale.
• Insitro: Machine learning-driven drug discovery combining computational biology with high-throughput data generation; comparable AI-platform biotech with pharma collaborations.
• BenevolentAI: UK-based AI drug discovery company using knowledge graphs and ML to identify novel targets; comparable geographic positioning and AI-for-drug-discovery thesis.
• Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to structure-based drug design; comparable AI-first platform positioning and pharma partnership model.
• Evariste Technologies: UK AI-driven small molecule discovery company and named co-development partner of Oppilotech; directly comparable ML-based ligand discovery approach for antibacterial programmes.

Emerging players

• Oxford Drug Design: UK-based early-stage company applying computational chemistry and ML to antibacterial discovery; comparable UK geography and AI-for-antibiotics focus at a similarly small scale.

Regional players

• LGC Group: UK-based life sciences measurement and testing company whose anti-infectives testing laboratories originated the bacterial isolate collection now used by Oppilotech; comparable microbiology services heritage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/oppilotech
• LinkedInlinkedin.com/company/oppilotech-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oppilotech